9,788 trials (keyword fallback)
Inflammation · Crohn's Disease
Primary: Percentage of Subjects Achieving a 70-point Decline in CDAI Scores (Crohn's Disease Activity Index) Scores; — 40; 88 percentage of pts — p=0.009
Crohn's Disease
Primary: Number of Patients Reporting Side Effects — 2; 2; 0; 2 participants — p=1.0
Celiac Disease
Primary: Number of Participants for Which Treatment Was Concluded to be Safe — 6; 18; 4; 5 participants
Crohn's Disease · Spondyloarthritis
Primary: Number of Participants With MRI Positivity- Global Assessment Positive — 4; 0 Participants
Crohn's Disease
Primary: Crohn's Disease Histologic Index of Severity (CDHIS) — 7; 8; 6; 8 scores on a scale
Crohn's Disease
Primary: Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of This Study CDP870-034 (up to 84 Months) — 94.2 percentage of subjects
HIV
Primary: Changes in Soluble Cluster of Differentiation 14 (sCD14) Levels Between the Placebo and Rifaximin Phases of the Study — 0.0067; 0.0035 mcg/mL — p=0.51
Colonic Neoplasms · Rectal Neoplasms · Diverticulitis
Primary: Anastomotic Leakage — 0 participants
Gastroschisis
Primary: Composition of the Fecal Microbiota — 42; 12; 1.1; 14 percentage of total bacteria — p=<0.01
Vitamin D Deficiency · Gastrointestinal Diseases
Primary: # of Pts w/ Enhanced Vitamin D Status — 3; 3 Participants
Small Bowel Crohn's Disease
Primary: Percentage of Participants Who Achieved Clinical Remission at Week 24 — 25.0; 25.0; 16.7 percentage of participants
Celiac Disease
Primary: Baseline Gastrointestinal Symptom Rating Scale (GSRS) Score — 2.7; 2.8 Score on a scale
Spondyloarthritis · Enterocolitis
Primary: Change Lewis Score Index — -225 units on a scale
Arthritis, Rheumatoid · Colitis, Ulcerative · Crohn Disease
Primary: Incidence Rate of Serious Infections — 0.06; 0.09; 0.22; 0.09 serious infections per 1 person-year
Crohn's Disease
Primary: Change in Bowel Wall Thickness (BWT) — 5; 4 mm